Possible therapies of septic shock: Based on animal studies and clinical trials

Current Pharmaceutical Design

Volumn 12, Issue 27, 2006, Pages 3535-3541

  Wu, C C ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Antioxidants; Cytokine modulation; Hydrocortisone; L NMMA; NOS inhibitors

Indexed keywords

ACETYLCYSTEINE; ACTIVATED PROTEIN C; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIOXIDANT; ANTITHROMBIN; ARGININE DERIVATIVE; CORTICOSTEROID; DIMETHYL SULFOXIDE; DOBUTAMINE; DROTRECOGIN; FREE RADICAL; GLUTATHIONE; HEPARIN; HYDROCORTISONE; I KAPPA B; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; NUCLEAR FACTOR; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; POLYCLONAL ANTIBODY; PROTON PUMP INHIBITOR; SUCRALFATE; TISSUE FACTOR PATHWAY INHIBITOR; TRANSCRIPTION FACTOR; UNINDEXED DRUG;

ADJUVANT THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; ERYTHROCYTE TRANSFUSION; GENE EXPRESSION REGULATION; HEMOFILTRATION; HUMAN; INFLAMMATION; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MORBIDITY; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SEPSIS; SEPTIC SHOCK; STRESS ULCER;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, SEPTIC;

EID: 33748757529     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778343019     Document Type: Review

References (82)

1. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit. Care Med 2001; 29(7 Suppl): S109-16.
2. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intens Care Med 2002; 28: 108-21.
3. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644-55.
4. Thiemermann C, Wu CC, Szabo C, Perretti M, Vane JR. Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. Br J Pharmacol 1993; 110: 177-82.
5. Szabo C, Wu CC, Gross SS, Thiemermann C, Vane JR. Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo. Eur J Pharmacol 1993; 250: 157-60.
6. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4.
7. Heumann D, Glauser MP. Anticytokine strategies for the treatment of septic shock: relevance of animal models. Curr Top Microbiol Immunol 1996; 216: 299-311.
8. Gendrel D, Assicot M, Raymond J, Moulin F, Francoual C, Badoual J, et al. Procalcitonin as a marker for the early diagnosis of neonatal infection. J Pediatr 1996; 128: 570-3.
9. Flowers F, Zimmerman JJ. Reactive oxygen species in the cellular pathophysiology of shock. New Horizons 1998; 6: 169-80.
10. Novelli GP. Role of free radicals in septic shock. J Physiol Pharmacol 1997; 48: 517-27.
11. Jimenez MF, Marshall JC. International Sepsis Forum. Source control in the management of sepsis. Intens Care Med 2001; 127(Suppl 1): S49-62.
12. Bochud PY, Glauser MP, Calandra T. International Sepsis Forum. Antibiotics in sepsis. Intens Care Med 2001; 27(Suppl 1):S33-48.
13. Fish DN. Optimal antimicrobial therapy for sepsis. Am J Health-System Pharm 2002; 59(Suppl 1): S13-9.
14. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. New Engl J Med 2001, 345: 1368-77.
15. Vincent JL. International Sepsis Forum. Hemodynamic support in septic shock. Intens Care Med 2001; 27(Suppi 1): S80-92.
16. Vincent JL, de Carvalho FB, De Backer D. Management of septic shock. Ann Med 2002; 34: 606-13.
17. Duranteau J, Sitbon P, Teboul JL, Vicaut E, Anguel N, Richard C, et al. Effects of epinephrine, norepinephrine, or the combination of norepinephrine and dobutamine on gastric mucosa in septic shock. Crit Care Med 1999; 27: 893-900.
18. Lebuffe G, Levy B, Neviere R, Chagnon JL, Perrigault PF, Duranteau J, et al. Dobutamine and gastric-to-arterial carbon dioxide gap in severe sepsis without shock. Intens Care Med 2002; 28; 265-71.
19. Schetz M. Vasopressors and the kidney. Blood Purif 2002; 20: 243-51.
20. Martin GS, Bernard GR. International Sepsis Forum. Airway and lung in sepsis. Intens Care Med 2001; 27(Suppl 1): S63-79.
21. Ebihara S, Hussain SN, Danialou G, Cho WK, Gottfried SB, Petrof BJ. Mechanical ventilation protects against diaphragm injury in sepsis: interaction of oxidative arid mechanical stresses. Am J Respir Crit Care Med 2002; 165: 221-8.
22. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1989; 17: 389-93.
23. Peigang Y, Marini JJ. Ventilation of patients with asthma and chronic obstructive pulmonary disease. Curr Opin Crit Care 2002; 8: 70-6.
24. Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 2003; 289: 2983-91.
25. Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. New Engl J Med 1998; 338: 791-7.
26. Mackenzie AR, Laing RB, Douglas JG, Greaves M, Smith CC. High prevalence of iliofemoral venous thrombosis with severe groin infection among injecting drug users in North East Scotland: successful use of low molecular weight heparin with antibiotics. Postgraduate Med J 2000; 76: 561-5.
27. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-50
28. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27: 723-32.
29. Briegel J, Jochum M, Gippner-Steppert C, Thiel M. Immuno-modulation in septic shock: hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 2001; 12(Suppl 17): S70-4.
30. van Leetriven HJ, van der Bruggen T, van Asbeck BS, Boereboom FT. Effect of corticosteroids on nuclear factor-kappaB activation and hemodynamics in late septic shock. Crit Care Med 2001; 29: 1074-7.
31. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2001; (2): CD001090.
32. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30: 100-6.
33. Amalich F, Lopez-Maderuelo D, Codoceo R, Lopez J, Solis-Garrido LM, Capiscol C, et al. Interleukin-1 receptor antagonist gene polymorphism, and mortality in patients with severe sepsis. Clin Exp Immunol 2002; 127: 331-6.
34. Griffin JH, Zlokovic B, Fernandez JA. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Seminars Hematol 2002; 39: 197-205.
35. Green J, Doughty L, Kaplan SS, Sasser H, Carcillo JA. The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. Thromb Haemost 2002; 87: 218-23
36. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001, 344: 699-709.
37. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-78.
38. Cross AS, Opal SM. A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann Internal Med 2003; 138: 502-5.
39. Grover R, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Crit Care Med 1999, 27: 913-22.
40. Grover R, Lopez A, Lorente J, Steingrub J, Bakker J, Willatts S, et al. Multi-center, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock (abstract). Crit Care Med 1999; 27:A33.
41. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-9.
42. Kuhns DB, Alvord WG, Gallin JI, Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 1995; 171: 145-52.
43. Norman JG, Sutton ET, Franz MS, Baker CH. Maintenance of dynamic microvascular function and structure in a rat model of endotoxic shock by blockade of the interleukin-1 receptor. Shock 1995; 3: 369-75.
44. Marchant A, Bruyns C, Vandenabeele P, Ducarme M, Gerard C, Delvaux A, et al. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994; 24: 1167-71.
45. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet 1997; 349: 1912-3.
46. Del Moral T, Goldberg RN, Urbon J, Suguihara C, Martinez O, Stein-Streilein J, et al. Effects of treatment with pentoxifylline on the cardiovascular manifestations of group B streptococcal sepsis in the piglet. Pediatric Res 1996; 40: 469-74.
47. Wu CC, Liao MH, Chen SJ, Yen MH. Pentoxifylline improves circulatory failure and survival in murine models of endotoxaemia. Eur J Pharmacol 1999; 373:41-9.
48. Lauterbach R, Zembala M, Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur J Pediatrics 1996; 155: 404-9.
49. Cannon JG, Tompkins RG, Gelfand JA, Michie HF, Stanford GG, van der Meer JW, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79-84.
50. Wheeler AP, Bernard GR. Treating patients with severe sepsis. New Engl J Med 1999; 340: 207-14.
51. Avontuur JA, Bruining HA, Ince C. Sepsis and nitric oxide. Adv Exp Med Biol 1996; 388: 551-67.
52. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051-64.
53. Hollenberg SM, Cunnion RE, Zimmerberg J. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats. Am J Physiol 1993; 264: H660-3.
54. Kilbourn RG, Szabo C, Traber DL. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Shock 1997; 7: 235-46.
55. Cobb JP. Nitric oxide synthase inhibition as therapy for sepsis: a decade of promise. Surg Infect 2001; 2: 93-100.
56. Kiehl MG, Ostermann H, Meyer J, Kienast J. Nitric oxide synthase inhibition by L-NAME in leukocytopenic patients with severe septic shock. Intens Care Med 1997; 23: 561-6.
57. Avontuur JA, Tutein Nolthenius RP, van Bodegom JW, Bruining HA. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit Care Med 1998; 26: 660-7.
58. Youn YK, LaLonde C, Demling R. Use of antioxidant therapy in shock and trauma, Circ Shock 1991; 35:245-9.
59. Kretzschmar M. Role of oxygen free radicals in the pathophysiology of sepsis. In: Reinhart Y, Eyrich K, Sprung C (eds), Sepsis: Current Perspectives in Pathophysiology and Therapy. Berlin, Springer-Verlag, 1994; pp 122-135.
60. Peralta IG, Llesuy S, Evelson P, Carreras MC, Flecha BG, Poderoso JJ. Oxidative stress in skeletal muscle during sepsis in rats. Circ Shock 1993; 39: 153-9.
61. Shindoh C, Dimarco A, Nethery D, Supinski G. Effect of PEG-superoxide dismutase on the diaphragmatic response to endotoxin. Am Rev Respir Dis 1992; 145:1350-4.
62. Schneider J, Friderichs E, Heintze K, Flohe L. Effects of recombinant human superoxide dismutase on increased lung vascular permeability and respiratory disorder in endotoxemic rats. Circ Shock 1990; 30: 97-106.
63. Broner CW, Shenep JL, Stidham GL, Stokes DC, Hildner WK. Effect of scavengers of oxygen-derived free radicals on mortality in endotoxin-challenged mice. Crit Care Med 1988; 16: 848-51.
64. Kunimoto F, Morita T, Ogawa R, Fujita T. Inhibition of lipid peroxidation improves survival rate of endotoxemic rats. Circ Shock 1987; 21: 15-22,
65. Zimmermann JJ. Potential of oxyradical scavengers in the therapy of sepsis. In: Reinhart K, Eyrich, Sprung C (eds), Sepsis: Current Perspectives in Pathophysiology and Therapy. Berlin, Springer-Verlag, 1994, pp 414-424.
66. Daryani I, LaLonde C, Zhu D, Demling RH. Changes in catalase activity in lung and liver after endotoxemia in sheep. Circ Shock 1990; 32: 273-80.
67. Seekamp A, Lalonde C, Zhu DG, Demling R. Catalase prevents prostanoid release and lung lipid peroxidation after endotoxemia in sheep. J Appl Physiol 1988; 65: 1210-6.
68. Milligan SA, Hoeffel IM, Goldstein IM, Flick MR. Effect of catalase on endotoxin-induced acute lung injury in unanesthetized sheep. Am Rev Respir Dis 1988; 137: 420-8.
69. Brackett DJ, Lerner MR, Wilson MF. Dimethyl sulfoxide antagonizes hypotensive, metabolic, and pathologic responses induced by endotoxin. Circ Shock1991; 33: 156-63.
70. McKechnie K, Furman BL, Parratt JR. Modification by oxygen free radical scavengers of the metabolic and cardiovascular effects of endotoxin infusion in conscious rats. Circ Shock 1986; 19: 429-39.
71. Meister A. On the antioxidant effects of ascorbic acid and glutathione. Biochem Pharmacol 1992; 44:1905-15.
72. Pacht ER, Timerman AP, Lykens MG, Merola AJ. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 1991; 100: 1397-403.
73. Ortolani O, Conti A, De Gaudio AR, Moraldi E, Cantini Q, Novelli G. The effect of glutathione and N-acetylcysteine on lipoperoxidative damage in patients with early septic shock. Am J Respir Crit Care Med 2000; 161: 1907-11.
74. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. New Engl J Med 1991; 24:1852-7.
75. Domenighetti G, Suter PM, Schaller MD, Ritz R, Perret C. Treatment with N-acetyleysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care 1997; 12: 177-82.
76. Henderson A, Hayes P. Acetylcysteine as a cytoprotective antioxidant in patients with severe sepsis: potential new use for an old drug. Ann Pharmacotherapy 1994; 28: 1086-8.
77. Spapen H, Zhang H, Demanet C, Vleminckx W, Vincent JL, Huyghens L. Does N-acetyl-L-cysteine mfluence cytokine response during early human septic shock? Chest 1998; 113:1616-24.
78. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 1996; 10: 709-20.
79. Meyer M, Schreck R, Baeuerle PA. H202 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 1993; 12: 2005-15.
80. Ganea D, Delgado M. The neuropeptides. VIP/PACAP and T cells: inhibitors or activators? Curr Pharm Design 2003; 9(12): 997-1004.
81. Murata A. Granulocyte colony-stimulating factor as the expecting sword for the treatment of severe sepsis. Curr Pharm Design 2003; 9(14): 1115-20.
82. Remick DG. Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Design 2003; 9(1): 75-82.